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Development of resistance to platinum compounds may involve not only overexpression of defence mechanisms but also alterations in cellular
response to the drug-induced genotoxic stress. To investigate the cellular bases of response to platinum compounds, we examined the profile of
gene expression of ovarian carcinoma cells exhibiting sensitivity (A2780) or resistance (A2780/BBR3464) to platinum compounds. Using display
PCR, we found that acquisition of resistance to the multinuclear platinum complex BBR3464 was associated with modulation of several
transcripts, including up-regulation of the major substrate of protein kinase C (PKC), the myristoylated alanine-rich C kinase substrate
(MARCKS). This feature was associated with PKCα down-regulation. To explore the role of PKCα in cellular sensitivity to platinum compounds,
resistant cells were transfected with a PKCα-containing vector. PKCα-overexpressing resistant cells exhibited a decrease in sensitivity to cisplatin,
whereas no significant change in sensitivity to BBR3464 was observed. A number of approaches designed to modulate the function or expression
of PKCα support that the isoenzyme may play a role in determining resistance only to cisplatin but not to BBR3464, which is known to activate a
different pathway of cell response. In conclusion, in spite of PKCα down-regulation in our model, its regulatory function was not apparently
implicated in the development of resistance to platinum compounds and the present results do not support a general role of PKCα as a determinant
of the resistance status.
© 2005 Elsevier B.V. All rights reserved.Keywords: Cisplatin; Platinum drug; Resistance; Protein kinase C1. Introduction
Platinum compounds are effective in the treatment of human
solid tumors, including ovarian carcinomas [1]. Nevertheless, a
major drawback in the clinical use of these cytotoxic agents is
the frequent development of resistance [2–4]. Despite the recent
advances in the cellular pharmacology of platinum compounds,
the molecular context contributing to the sensitivity or
resistance to the drugs has not been conclusively defined.
Over the years, several mechanisms of resistance have been
described. They include altered drug accumulation [5,6],
reduced interaction with the intracellular target, enhanced
DNA repair [4,7] and increased detoxification [8,9]. Reduced
susceptibility to apoptosis has also been proposed as a⁎ Corresponding author. Tel.: +39 02 23902237; fax: +39 02 23902692.
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including platinum compounds [10–13]. Moreover, alterations
in the signal transduction pathways can affect cellular response
to cytotoxic drugs [14,15]. In an attempt to identify critical
determinants of cellular response to platinum compounds, we
have performed a comparative study with display PCR and gene
expression analysis in ovarian carcinoma cells sensitive to
platinum drugs and in a subline selected for resistance to
BBR3464, a multinuclear Pt complex characterized by a
marked cytotoxic potency [16]. In the resistant cell line, we
found up-regulation of the myristoylated alanine-rich C kinase
substrate (MARCKS), the major and ubiquitous substrate of
protein kinase C (PKC), but a down-regulation of PKCα. Since
PKCα has been implicated in several biological processes
including proliferation and drug resistance, using this cell model
we investigated the role of PKCα as potential modulator of
sensitivity to platinum compounds. The available results do not
94 S.C. Righetti et al. / Biochimica et Biophysica Acta 1763 (2006) 93–100support a general role of PKCα as determinant of resistance to
Pt compounds.
2. Materials and methods
2.1. Drugs and chemicals
Cisplatin and BBR3464 (NO3
− salt), were primarily dissolved in saline. All
working dilutions were prepared in saline. Gö6976 (Calbiochem, San Diego,
CA) was dissolved in dimethylsulfoxide and diluted in water. Phorbol 12,13-
dibutyrate (PDBu; Sigma, St. Louis, MO, USA) was dissolved in dimethylsulf-
oxide and diluted in dimethylsulfoxide.
2.2. Cell lines and growth conditions
The human ovarian carcinoma A2780 cell line and the BBR3464-
resistant A2780/BBR3464 subline were used in this study [17]. A2780/
BBR3464 cells were generated by continuous exposure to increasing
concentrations of drug. Resistance was stable up to 9 months when cells
were grown in the absence of drug. The growth characteristics of sensitive
and resistant cells were similar. Both cell lines were grown and maintained
as monolayers in RPMI-1640 medium supplemented with 10% fetal calf
serum (Invitrogen, Carlsbad, CA).
2.3. Cellular sensitivity to drugs
Cellular sensitivity to platinum drugs or to Gö6976 was evaluated by
colony-forming or growth-inhibition assays [18]. For colony-forming assays,
cells in the logarithmic phase of growth were seeded in duplicates into 5 cm
diameter dishes. Forty-eight h after seeding, the drug was added to the medium
for 1 h. Cells were then washed with saline prior to addition of fresh medium.
Seven days after treatment colonies of 30 or more cells were counted after fixing
in ethanol and staining with crystal violet. IC50 is defined as the drug
concentration causing a 50% reduction of colony number over that of untreated
control.
For growth-inhibition assays, cells were seeded in duplicates into 6-well
plates. Twenty-four h after seeding, the drug was added to the medium for 1
h and cells were incubated for 72 h. Gö6976 was added to the medium for 72
h before harvesting for counting. For combination with Gö6976, cells were
treated for 1 h with cisplatin and then incubated for 72 h with 0.03 μMGö6976.
For combinations with PDBu, cells were treated with 1 μM PDBu for 15 min
(short-term exposure) or 24 h (long-term exposure) before addition of cisplatin
for 1 h. At the end of drug exposure (for 72 h treatment) or 72 h after drug
treatment (for 1 h exposure) adherent cells were harvested using trypsin and
counted with a cell counter.
2.4. Analysis of drug interaction
According to the method of Kern et al. [19], the expected value of cell
growth (Gexp, defined as the product of the growth observed with drug A alone
and the growth observed with drug B alone) and the actual growth observed
(Gobs) for the combination of A and B were used to construct a synergistic index
(R), as follows:
R ¼ Gexp=Gobs
Synergy was defined as any value of R greater than unity. An R value of 1.0
(additive effect) or less indicated an absence of synergy.
2.5. Differential display assay
Cytoplasmic RNA from A2780 and A2780/BBR3464 was isolated by
using the RNeasy Midi kit (Qiagen, Santa Clarita, CA) and fingerprinted by
the Delta Differential Display kit (Clontech, Palo Alto, CA). Briefly, first-
strand cDNA was synthesized using 2 μg of RNA, oligo(dT) as a primer,
and Moloney murine leukemia virus reverse transcriptase. Two dilutions ofeach cDNA template (corresponding to 50 and 200 ng of reverse transcribed
RNA) were amplified by PCR in the presence of 50 μM dNTPs, 1 μM
primers, 50 nM [α-33P]dATP (1000–3000 Ci/mmol; Amersham Pharmacia
Biotech; Cologno Monzese, Italy), 1× Advantage KlenTaq polymerase and
reaction buffer (Clontech). The PCR primers used were a pairwise
combination of arbitrary “P” (P1–P2) and oligo(dT) “T” (T1–T4) primers.
Amplification conditions were as follows: 94 °C for 5 min, 40 °C for 5 min,
68 °C for 5 min for 1 cycle; 94 °C for 2 min, 40 °C for 5 min, and 68 °C
for 5 min for 2 cycles; 94 °C for 1 min, 60 °C for 1 min, and 68 °C for 2
min for the remaining 24 cycles. The last cycle was followed by a 10 min
extension at 72 °C. PCR products were fractionated in a 6% polyacrylamide/
8 M urea gel and visualized by autoradiography. The differentially expressed
band in the A2780/BBR3464 was eluted from the gel, reamplified, blunt-
ended, subcloned into the pMOSBlue vector using the pMOSBlue blunt
ended cloning kit (Amersham Pharmacia Biotech) and automatically
sequenced using the ABIPRISM Dye Terminator cycle sequencing ready
reaction kit (PerkinElmer Corp., Brounchburg, NJ). Nucleotide sequence was
subjected to BLAST searches for sequence homologies (National Center for
Biotechnology Information).
2.6. Western blot analysis
Cell lysates from exponentially growing cells were prepared as previously
described with minor modifications [20]. Samples (80 μg/lane) were
fractionated by SDS-polyacrylamide gel electrophoresis and blotted on
nitrocellulose sheets. Blots were preblocked for 1 h at room temperature in
PBS containing 5% (w/v) dried nonfat milk. Filters were incubated overnight at
4 °C with monoclonal antibodies to PKC isoenzymes (Transduction
Laboratories, Lexington, KY), to MARCKS (Upstate Biotechnology, Lake
Placid, NY), to phospho-MARCKS (Calbiochem), to p53 (DakoCytomation,
Glostrup, Denmark), to p21WAF1 (NeoMarkers, Fremont, CA), to Caspase-3
(Calbiochem) and to PKCζ (Upstate Biotechnology). A rabbit anti-actin
antibody (Sigma) was used as control for loading. Antibody binding to the
nitrocellulose blots was detected by enhanced chemiluminescence (Amersham
Pharmacia Biotech).
2.7. PKC activity assay
The soluble and particulate fractions were prepared and fractions were tested
for PKC activity as described [21,22], by measuring the amount of 32P
incorporated into histone IIIS (Sigma) from [γ-32P]ATP (sp. act. 3000 Ci/mmol;
Amersham) in the presence of phospholipids (PS and 1,2-dioleoylglycerol) and
CaCl2. Background activity was measured with EGTA in the absence of
phospholipids.
2.8. Transfection of recipient cells
Transfections were carried out by lipofection as previously described
with minor modifications [23]. Cells were seeded in 6-well plates and when
they reached 70% confluency each well was incubated for 6 h with serum-
free medium containing 30 μl of lipofectin (Invitrogen) and 3 μg of empty,
PKCα- or MARCKS-containing vectors. Medium was replaced with serum-
containing medium and 48 h later selection of stable clones was started by
adding 200 μg/ml geneticin (Invitrogen). Protein expression was monitored
by Western blot analysis. The plasmid containing the PKCα bovine sequence
driven by pCMV was kindly provided by Dr. P.J. Parker (London, UK). The
plasmid containing the human MARCKS cDNA [24] was kindly provided
by Dr. P.J. Blackshear and Dr. D.J. Stumpo (Research Triangle Park, NC,
USA).
2.9. Cell cycle analysis
Exponentially growing cells were seeded in 25 cm2 flasks and 24 h later,
they were exposed to drug for 1 h. Drug-containing medium was then replaced
with fresh medium and cell cycle analysis was carried out after 24 h. Floating
and adherent cells were harvested, fixed and stained with a propidium iodide
(PI)-containing solution (30 μg/ml PI, 66 U/ml RNase A in PBS). The cell cycle
Table 1
Sensitivity of ovarian carcinoma cells to cisplatin and BBR3464 a
IC50 (μg/ml)
Cisplatin BBR3464
A2780 0.72±0.1 0.046±0.004
A2780/BBR3464 3.19±0.9 1.47±0.3
a Cytotoxicity was assessed by colony-forming assay. Cells were exposed for
1 h to the drug. IC50 values (drug concentration inhibiting colony formation by
50%) represent the mean±S.D. of at least 3 independent experiments.
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Franklin Lakes, NJ). Ten thousand cells/sample were analyzed for DNA content
and cell cycle distributions were calculated using WinMDI software.3. Results
3.1. Analysis of gene expression
The A2780/BBR3464 subline was selected for resistance
to BBR3464 and exhibited a cross-resistance to cisplatin
(Table 1) [17]. Using display PCR the mRNA expression
pattern of BBR3464-sensitive and -resistant cells was
compared using different combinations of arbitrary andTable 2
List of the cDNA clones identified by differential display analysis
Accession number a Matching b High-scoring sequence
D10522 1991–2496 Human mRNA for 80K-L protein
X52142 877–1202 Human mRNA for CTP synthetase
M81757 167–495 H. sapiens S19 ribosomal
protein mRNA
X05608 4084–4408 Human gene for
neurofilament subunit NF-L
AH006432 2295–2635 H. sapiens brain
cellular apoptosis susceptibility
protein (CSE1/CAS) mRNA
X77303 682–1020 H. sapiens CAK1 mRNA
for cdk-activating kinase
(CDK7)
AF161444 1321–1614 H. sapiens HSPC326
mRNA
X55187 1627–1965 Human mRNA for alpha-actinin
D90228 758–1102 Human mRNA for
acetoacetyl-CoA thiolase
M15182 1828–2178 Human
beta-glucuronidase mRNA
U30827 893–1256 Human splicing factor
Arg/ser-rich SRp40-3
a Genbank accession number.
b bp (from–to) of the high-scoring sequence matching the sequenced fragment.
c Up (↑)- or down (↓)-modulation in A2780/BBR3464 versus A2780 cells.oligo-dt primers. We identified several bands that were
reproducibly modulated in the A2780/BBR3464 cells. The
bands were excised, re-amplified, cloned, sequenced and
analyzed against the Genbank database. The isolated cDNA
clones, which are shown in Table 2 included genes belonging
to different pathways such as Cellular Apoptosis Suscepti-
bility gene (CAS), beta-glucoronidase, S19 ribosomal protein,
and acetoacetyl CoA tiolase. Among the modulated tran-
scripts, we also found neurofilament low (NF-L), for which
we have already documented lack of involvement in the
resistant phenotype [17], and as shown in Fig. 1A, the
mRNA encoding MARCKS, a ubiquitous substrate of PKC
involved in different cellular responses including cell motility,
secretion, cell cycle, transformation, regulation of actin
cytoskeleton [25].
3.2. Validation of differential expression
Validation of differentially expressed genes was undertaken by
Western blot or RT-PCR analysis. Some modulations were not
confirmed as expected on the basis of the high rate of false
positives reported for the display PCR approach [3,26]. Western
blot analysis using an antibody against MARCKS indicated aFunction Modulation c
Substrate for PKC, localized to the plasma membrane;
actin filament crosslinking protein. Involved in
cell motility, phagocytosis, membrane trafficking
and mitogenesis.
↑
It catalyzes the ATP-dependent amination of UTP to
CTP with either L-glutamine or ammonia as the
source of nitrogen.
↑
Ribosomal protein ↓
Protein belonging to the intermediate filament family ↑
Export receptor for importin alpha. It mediates
importin-alpha reexport from the nucleus to the
cytoplasm after import substrates have been released
into the nucleoplasm. It plays a role in apoptosis and
in cell proliferation.
↓
Member of the cyclin-dependent protein kinase
(CDK) family. Involved in transcription initiation
and DNA repair. It is thought to serve as a direct link
between the regulation of transcription and
the cell cycle.
↓
Not known ↑
F-actin cross-linking protein thought to anchor actin
to intracellular structures. Bundling protein
↑
It plays a major role in ketone body metabolism ↓
Role in the degradation of dermatan and
keratan sulfates
↓
Role in constitutive splicing and selection
of alternative splice sites
↓
Fig. 1. Display PCR and Western blot analysis in A2780 and A2780/BBR3464
cells. (A) Display PCR; the arrow indicates the differentially expressed band
corresponding to MARCKS. (B) Western blot analysis of MARCKS and p-
MARCKS. Control loading is shown by actin. (C) Western blot analysis of
different PKC isoforms. Control loading is shown by actin.
Fig. 2. MARCKS expression and PKC expression/activity in transfected cells.
(A) Western blot analysis of MARCKS expression after transfection with
MARCKS-containing vector (A2780-MARCKS poly and clone) and empty
vector (A2780-e). Control loading is shown by actin. (B) Western blot analysis
of PKCα expression after transfection with PKCα-containing vector (A2780/
BBR-PKCα) and empty vector (A2780/BBR-e). Control loading is shown by
actin. (B) Activity of calcium-dependent PKC. PKC activity in the soluble (open
columns) and particulate (solid columns) fractions, expressed as enzyme activity
pmol 32P/min/103 cells. Each bar represents the mean value (±S.D.) of at least 3
independent experiments.
96 S.C. Righetti et al. / Biochimica et Biophysica Acta 1763 (2006) 93–100substantial up-regulation of the protein in the drug-resistant subline
(Fig. 1B). Using a phospho-specific antibody, we found that
MARCKS was phosphorylated in A2780/BBR cells (Fig. 1B).
3.3. Expression of PKC isoenzymes
As MARCKS is the major and ubiquitous substrate of PKC,
which includes a family of at least 13 distinct serine/threonine
kinases [27], we investigated the expression of PKC iso-
enzymes in BBR3464-sensitive and -resistant cells. Western
blotting analysis indicated that PKC β, γ, η, and θ were not
detectable in A2780 and A2780/BBR3464 cells (data not
shown), whereas PKC δ, ε, ζ and ι/λ were markedly expressed
at similar levels (Fig. 1C). An unexpected finding was a down-
regulation of PKCα, which has been implicated in cell survival
[28], in the resistant variant as compared with the parental cell
line (Fig. 1C). Activity experiments of calcium-dependent
protein kinases were consistent with differential expression as
total activity was 4.7 pmol 32P/min/103 cells in A2780 cells and
1.9 in A2780/BBR3464 cells.
3.4. Transfection of MARCKS into A2780 cells
To define whether MARCKS played a role in regulation of
cell sensitivity to platinum drugs, we transfected A2780 cells
with a plasmid containing the MARCKS full-length cDNA.
Using Western blot analysis, we selected a clone and a
polyclonal population overexpressing the protein (Fig. 2A).
An analysis of cell sensitivity to cisplatin or BBR3464 (1
h exposure) with growth-inhibition assays indicated that
modulation of cellular levels of MARCKS per se was not
sufficient to change drug sensitivity. In fact, the IC50 values ofA2780-MARCKS poly cells (2.37±0.13 μg/ml for cisplatin and
0.021±0.00035 μg/ml for BBR3464) or A2780-MARCKS
clone (1.91±0.29 μg/ml for cisplatin and 0.022±0.003 μg/ml
for BBR3464) were not significantly different from those of
empty vector-transfected A2780 cells (2.8±0.8 μg/ml for
cisplatin and 0.017±0.008 μg/ml for BBR3464).
3.5. Phenotype of A2780/BBR3464 cells overexpressing PKCα
To determine whether down-regulation of PKCα was related
to the development of resistance in the BBR3464-resistant cells,
A2780/BBR3464 cells were transfected with a plasmid
expressing the PKCα full-length cDNA. Using Western blot
analysis, we identified a clone overexpressing the protein (Fig.
2B). The sensitivity of the clone to the PKCα specific inhibitor
Gö6976 was increased as compared to empty vector transfected
Table 3
Sensitivity of ovarian carcinoma PKCα-transfected cells to cisplatin and
BBR3464 a
IC50 (μg/ml)
Cisplatin BBR3464
A2780/BBR-e 2.89±0.38 2.34±0.61
A2780/BBR-PKCα 4.97±0.94 2.25±0.6
a Cell sensitivity was assessed by growth-inhibition assay on cells transfected
with PKCα containing vector (A2780/BBR-PKCα) and empty vector (A2780/
BBR-e). Cells were exposed for 1 h to the drug. IC50 values (drug concentration
inhibiting colony formation by 50%) represent the mean±S.D. of at least 3
independent experiments.
Table 4
Cell cycle perturbations induced by cisplatin or BBR3464 a
A2780/BBR-e A2780/BBR-PKCα
G1 S G2/M G1 S G2/M
Control 59.9 27.2 12.9 52.6 31.3 16.1
1 μg/ml BBR3464 68.5 19.8 11.7 67.7 20.1 12.2
3 μg/ml BBR3464 77.3 13.4 9.3 73 13.9 13
10 μg/ml BBR3464 83.5 7.3 9.2 75.6 10.7 13.8
30 μg/ml BBR3464 84.2 7.9 7.9 67 11.5 21.5
1 μg/ml Cisplatin 63.8 21.4 14.8 57.7 28.4 14
3 μg/ml Cisplatin 73.2 16.7 10.1 65.3 20.3 14.4
10 μg/ml Cisplatin 61.1 9.7 29.2 59.7 17.2 23.2
30 μg/ml Cisplatin 23.5 41.5 35.0 28.6 51.1 20.3
a Cells were exposed to drug for 1 h and harvested 24 h after drug removal.
Values represent percent of cells in different cell cycle phases. A2780/BBR-e
and A2780/BBR-PKCα cells were derived by transfection of A2780/BBR3464
cells with empty or PKCα vector.
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exposure. Indeed, IC50 was 1.6 μM in PKCα transfected cells
and 10 μM in empty vector-transfected cells. The enzymatic
activity of Ca2+ and lipid-dependent kinases (including PKCα)
was assayed in the soluble and particulate fractions. We found
that A2780/BBR-PKCα cells displayed an increased activity in
both fractions (Fig. 2C).
Due to the interplay between PKC isoforms, overexpression
of specific enzymes can result in changes in expression of other
isoforms [29]. Thus, we investigated whether PKCα over-
expression modulated expression of PKC isoenzymes. In our
cell systems, no significant changes were revealed in A2780/
BBR-PKCα cells versus cells transfected with empty vector
(data not shown). Moreover, no modulation of MARCKS
expression was observed in PKCα transfectants, suggesting that
overexpression of the PKC substrate MARCKS in A2780/
BBR3464 cells was not a homeostatic change resulting from
reduced levels of the kinase (data not shown).
The model was further characterized to investigate the
biological significance of specific alterations related to
modulation of PKCα expression. In particular, to define the
possible involvement of PKCα in regulating cellular sensitivity
to platinum drugs, we performed a growth-inhibition assay
after 1 h drug exposure. Under our experimental conditions,
A2780/BBR-PKCα cells displayed an increased resistance to
cisplatin as compared to empty vector-transfected cells
(Pb0.05, ANOVA; Table 3), whereas cell sensitivity to
BBR3464 was unchanged. Using a colony-forming assay, to
detect long-term survival of treated cells, a slight but not
significant increase of BBR3464 cytotoxicity in A2780/BBR-
PKCα cells was observed (IC50 was 1.3±0.3 μg/ml in PKCα
transfected cells and 1.68±0.25 μg/ml in empty vector-
transfected cells).
As exposure to platinum drugs is known to induce cell cycle
perturbations which play a protective role in response to DNA
damage, we examined cell cycle distribution in empty vector-
and A2780/BBR-PKCα cells following 1 h exposure to
cisplatin or BBR3464 and 24 h incubation in drug-free medium.
BBR3464 produced G1 arrest in both cell lines at all tested
concentrations (Table 4). At 30 μg/ml BBR3464, a partial G2
arrest was also evident in PKCα overexpressing cells. Cisplatin
exposure resulted in G1 arrest at low concentrations in both cell
lines, whereas a S phase and G2 accumulation of cells was
found at higher drug concentrations.Based on the observed cell cycle perturbations, we explored
drug-induced modulation of proteins involved in checkpoint
control. Western blot analysis of p21WAF1 revealed that the
protein was induced after cisplatin and BBR3464 treatment, the
extent being lower in A2780/BBR-PKCα cells as compared to
empty vector-transfected cells (Fig. 3A). The up-regulation of
p53 after DNA damage was evident in both cell lines and was
more marked after cisplatin exposure (Fig. 3A).
To investigate whether the differential cell sensitivity to
platinum drugs of PKCα overexpressing cells was associated
with changes in apoptotic response, we examined cleavage of
caspase 3 following exposure to 30 μg/ml BBR3464 or
cisplatin. No marked difference in caspase 3 cleavage was
observed between A2780/BBR-PKCα and A2780/BBR-e cells
after BBR3464 exposure, whereas reduced levels of cleaved
caspase were found after cisplatin exposure (Fig. 3B). The
reduction of cleaved caspase 3 was dose-dependent (Fig. 3C).
The observation is consistent with the reduced antiproliferative
effect observed following cisplatin exposure in A2780/BBR-
PKCα cells.
3.6. Combination of PKC modulators and platinum compounds
To investigate whether the PKCα inhibitor Gö6976 was
capable of modulating cell sensitivity to cisplatin and
BBR3464, we performed growth-inhibition assays after 1
h cisplatin or BBR3464 exposure followed by 72 h exposure
to Gö6976 in A2780 cells. The modulation of drug effect by
Gö6976 was assessed using R index, whose values are greater
than 1 when synergistic interaction occurs. Under our
experimental conditions, Gö6976 produced a marginal sensiti-
zation to cisplatin, but not to BBR3464, at cytotoxic
concentrations (i.e., N1 μM; Fig. 4).
We examined the effect of short- and long-term exposures to
the PKC activator PDBu on cisplatin sensitivity. PDBu was
chosen because it is less hydrophobic then TPA and therefore
more appropriate for in vitro experiments. Cells were treated for
15 min (short-term exposure) or 24 h (long-term exposure) with
1 μM PDBu, and then exposed to cisplatin for 1 h. The results,
Fig. 3. Modulation of selected proteins by drug treatment in PKCα-transfected
cells. (A) Western blot analysis of p53 and p21WAF1. Cells were exposed for 1
h to 30 μg/ml cisplatin or BBR3464 and harvested 24 h later. Control loading is
shown by actin. (B) Western blot analysis of cleaved caspase 3. Cells were
exposed for 1 h to 30 μg/ml cisplatin or BBR3464 and harvested 24 h later.
Control loading is shown by actin. (C) Western blot analysis of cleaved caspase
3. Cells were treated for 1 h with different cisplatin concentrations and harvested
24 h later. Control loading is shown by actin. A2780/BBR-e and A2780/BBR-
PKCα cells were derived by transfection of empty or PKCα-containing vector in
A2780/BBR cells.
Fig. 4. Combination of platinum drugs and Gö6976 in A2780 cells. Cells were
exposed for 1 h to cisplatin or to BBR3464 and then incubated for 72 h with 0.03
μM Gö6976. Cell sensitivity to treatment was assessed by growth-inhibition
assay and the effect of the combination was evaluated using the R index.
Fig. 5. Combination of cisplatin and PDBu in PKCα overexpressing cells. Cells
were exposed to cisplatin for 1 h after 15 min (A) or 24 h (B) pre-incubation with
1 μM PDBu. Cell sensitivity to treatment was assessed by growth-inhibition
assay. The results are reported in terms of R index. A2780/BBR-e, empty vector
transfected cells; A2780/BBR-PKCα, A2780/BBR cells overexpressing PKCα.
98 S.C. Righetti et al. / Biochimica et Biophysica Acta 1763 (2006) 93–100expressed as R index, indicated no significant modulation of
cisplatin sensitivity after short-term exposure (Fig. 5). Con-
versely, long-term treatment with PDBu (that results in PKC
down-regulation) [30] produced a marginal sensitization to
cisplatin only in A2780BBR-e cells at highly cytotoxic
concentrations (10 μM), therefore suggesting that in PKCα-
overexpressing cells a complete down-regulation of PKCα
could not be achieved by treatment.
4. Discussion
The present study shows modulation of several transcripts,
including MARCKS, NF-L, CAS, beta-glucoronidase, S19
ribosomal protein, and acetoacetyl CoA thiolase in cells
resistant to platinum drugs. Among the modulated transcripts,
we focused on the myristoylated alanine-rich C kinase substrate
(MARCKS, Fig. 1A, B), because it is the major and ubiquitous
substrate of PKC, and the PKC pathway is known to be
implicated in modulation of several critical events including cell
growth, cell cycle progression and apoptosis [27]. Transfection
of a MARCKS-containing plasmid into A2780 cells did not
result in a significant change in sensitivity to platinum drugs.
This observation does not support a role of MARCKS itself in
modulating drug sensitivity. On the basis of the substantial up-
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subline, the down-regulation of PKCα was an unexpected
finding (Fig. 1C). In contrast, we did not observe modulation of
PKCδ (Fig. 1C), which has been associated with modulation of
sensitivity to cisplatin [31–34].
PKCs are a family of isoenzymes differentially implicated in
the transduction of signals for proliferation, differentiation and
apoptosis, but the role of specific PKC isoforms in drug
resistance remains to be defined [27,35]. PKC signal transduc-
tion pathway has been reported to play a role in modulating cell
death mediated by cisplatin [34,36]. Some PKC members are
substrates for caspase 3 activated during drug-induced apopto-
sis and proteolytic activation of PKC-δ has been implicated in
cellular response to cisplatin [31–34]. In contrast, PKCα has
been described as an antiapoptotic protein [28]. However, the
development of resistance to BBR3464 and cross-resistance to
cisplatin in A2780/BBR cells, characterized by down-regula-
tion of PKCα, suggest that the PKCα pathway was not
implicated in the resistance mechanisms. In addition, our results
do not support a general protective function of PKCα, because
transfection of A2780/BBR cells with PKCα resulted in an
increased resistance only to cisplatin, as shown by increase in
IC50 value as well as by decreased cleavage of caspase 3 (Table
3, Fig. 3B, C). In keeping with this finding is the observation
that the PKCα inhibitor Gö6976 potentiated the effect of
cytotoxic concentrations of cisplatin but not of BBR3464 in
A2780 cells.
As already reported for other PKC isoforms [34], the
function of PKCα could be dependent on the nature of cellular
response which may be related to the extent and type of DNA
damage. The controversial data reported on the role of PKCα
could reflect the complexity of multiple functions. PKCα has
been implicated as a prosurvival factor in response to cytotoxic
injuries and therefore it is recognized as a potential determinant
of drug resistance [35]. Since cisplatin and BBR3464 are known
to induce different patterns of cellular response [37], it is
possible that PKCα may have a different role in the various
pathways activated by specific types of injury. An additional
protective function of PKCα could be ascribed to functional
activation of enzymes involved in mechanisms of cellular
protections through xenobiotic metabolism. In particular, the
activation of glutathione-S-transferase P1 (GST-P1) by PKC-
dependent phosphorylation could contribute to cell protection
resulting in tumor cell resistance to agents metabolized by GST
(e.g., electrophilic compounds) [38]. A tentative explanation for
the differential response of PKCα-transfected cells to cisplatin
and to the multinuclear platinum complex could be a different
GSH interaction of the two complexes, resulting in an increased
inactivation of cisplatin. GST-P1 itself plays a role in stress
response and signaling [39,40].
In conclusion, the development of resistance in the A2780/
BBR subline and the cross-resistance to cisplatin, in spite of
down-regulation of PKCα, support that the resistance mecha-
nism is independent of PKCα function. The available results do
not support a general protective role of PKCα in response to
genotoxic stress. Its antiapoptotic function or its regulatory
function on cellular response pathways likely depends onparticular circumstances related to the nature of cytotoxic stress
or to the biological context.
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